Nadav Kidron, CEO of Oramed Pharmaceuticals, holds insulin pills as he poses for a photo at the company's offices in Jerusalem September 29, 2013. (REUTERS/Baz Ratner)
Oramed, an Israeli developer of oral drug delivery systems, said on Thursday a mid-stage trial for its oral insulin capsule for the treatment of type 2 diabetes met all primary and secondary endpoints.
During the Phase 2a trial, conducted under a U.S. Food and Drug Administration new drug protocol, 30 patients with type 2 diabetes took part in an in-patient setting for one week.
Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated.
"We are extremely pleased with the results, which give a solid validation for Oramed's platform technology in general and our oral insulin programme in particular," said Nadav Kidron, Oramed's chief executive.
Kidron said the company is planning a Phase 2b study later in 2014 and will initiate a Phase 2a FDA study for type 1 diabetes in the near term.
Fox News Health
Stay up-to-date on the biggest health and wellness news with our weekly recap.
By entering your email and clicking the Subscribe button, you agree to the Fox News Privacy Policy and Terms of Use, and agree to receive content and promotional communications from Fox News. You understand that you can opt-out at any time.